Sadık Volkan EMREN, FATİH ADA, Mustafa ALDEMİR, Ersel ONRAT

Is Thromboembolic Risk Level Different Between Patients with and without Atrial Fibrillation Suffering from Peripheral Arterial Embolism?

Objective: CHA2DS2-VASc [congestive heart failure / left ventricular dysfunction,hypertension, age≥75 years (doubled), diabetes, stroke (doubled)– vascular disease, 65–74 years of age, and female sex ]is a validated ,straightforward and practical stratification of thromboembolic risk scorefor non-valvular atrial fibrillation (NVAF). However it is usually used forstroke. In this trial we aim to compare the CHA2DS2-VASc score betweenpatients with and without AF suffering from peripheral arterial embolism (PAE).Materials and Methods: We retrospectively evaluated the data registries of 150 patients who admitted tohospital due to PAE between January 2011- December 2016. CHA2DS2-VASc score was calculated foreach patientResults: Atrial fibrillation was detected 59% of patients. Patients with AF were elder, more often femalegender, hypertension, heart failure, hyperlipidemia, stroke and transient ischemic attack (p0.05). Patients with AF had higher CHA2DS2-VASc scorethen those without AF (5.1±1.7 vs 3.5±1.8 p

Periferik Arter Embolisi Geçiren Atriyal Fibrilasyonu Olan ve Olmayan Hastaların Tromboembolik Risk Düzeyi Birbirinden Farklı mıdır?

Amaç: CHA2DS2-VASc [Konjestif kalp yetmezliği/sol ventrikül disfonksiyonu, hipertansiyon, yaş ≥75 yıl (çift puan), diyabet, inme (çift puan)- vasküler hastalık, 65-74 yaş ve kadın cinsiyet] skoru atriyal fibrilasyona (AF) bağlı tromboembolik komplikasyonların risk sınıflandırmasında kullanılan geçerli, pratik bir yöntemdir. Fakat klinik pratikte kullanımı daha çok inme için olmaktadır. Bu çalışmada periferik arteriyel emboli (PAE) geçiren AF’li ve AF’li olmayan hastaların CHA2DS2-VASc skoru karşılaştırılmıştır. Gereç ve Yöntem: Bu çalışmada ocak 2011 ve aralık 2016 tarihleri arasında periferik arteryel emboli tanısı alan 150 hastanın kayıtları geriye dönük taranmıştır. Tüm hastaların olay öncesi CHA2DS2-VASc skoru hesaplanmıştır. Bulgular: Hastaların %59’unda AF saptandı. AF’li hastaların yaş ortalaması, kadın cinsiyet, hipertansiyon , kalp yetmezliği , hiperlipidemi ve inme oranı daha yüksek izlenmiştir (p

PDF

___

Hsu PC, Chiu CA, Chu CY, Lee WH, Su HM, Lin TH,et al CHADS2 Score and Risk of New-onset Peripheral Arterial Occlusive Disease in Patients without Atrial Fibrillation: A Nationwide Cohort Study in Taiwan. J Atheroscler Thromb. 2015; 22 (5):490-8.
Hazanov N, Attali M, Somin M, Beilinson N, Goland S, Katz M et al Splenic Embolus: 13 Cases from a Single Medical Department. Isr Med Assoc 2006; 8(10): 94–7.
Chu PL, Wei YF, Huang JW, Chen SI, Chu TS, Wu KD. Clinical characteristics of patients with segmental renal infarction. Nephrology (Carlton). 2006; 11(4):336–40.
Acosta S, Ogren M, Sternby NH, Bergqvist D, Björck M.: Fatal nonocclusive mesenteric ischaemia: population- based incidence and risk factors. J Intern Med 2006; 259(3):305–13
Frost L, Engholm G, Johnsen S, Moller H, Henneberg EW, Husted S: Incident thromboembolism in the aorta and the renal, mesenteric, pelvic, and extremity arteries after discharge from the hospital with a diagnosis of atrial fibrillation Arch Intern Med 2001; 161(2):272–6.
Wasilewska M, Gosk-Bierska I. Thromboembolism associated with atrial fibrillation as a cause of limb and organ ischemia. Adv Clin Exp Med 2013; 22(6):865-73.
Karapolat S, Dag O, Abanoz M, Aslan M. Arterial embolectomy: a retrospective evaluation of 730 cases over 20 years. Surg Today 2006; 36(5):416-9.
abag S, Duval S, Chrolavicius S et al. Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes. Circulation. 2015; 132(9):796-803.
Silvers LW, Royster TS, Mulcar RJ: Peripheral arterial emboli and factors in their recurrence rate. Ann Surg 1980; 192(2):232–6
Cardiol 2000;74(4):324–7. 7- Cambria R P, Abbott WM: Acute arterial thrombosis of the lower extremity. Its natural history contrasted with arterial embolism. Archiv Surgery 1984; 119(7):784–7.
Barretto PCA, Nobre MRC, Mansur AJ, Scipioni A, Ramires JA F: Peripheral Arterial Embolism. Report of Hospitalized Cases. Arq Bras Cardiol 2000;74(4):324–7.
Lip GYH and Edwards SJ, “Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis,” Thrombosis Research 2006; 118(3):321–33
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38):2893-962.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137(2):263–72.
Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH et al: Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27(8):949–53
Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip GY. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke. 2013; 44 (5):1329–36.